2-(3-溴-5-甲酰基-4-((2-甲氧基乙氧基)甲氧基)苯基)琥珀酸二甲酯 | 878673-54-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 中文名称: 2-(3-溴-5-甲酰基-4-((2-甲氧基乙氧基)甲氧基)苯基)琥珀酸二甲酯
• 英文名称: 2-[3-Bromo-5-formyl-4-(2-methoxy-ethoxymethoxy)-phenyl]-succinic acid dimethyl ester
• 英文别名: Dimethyl 2-(3-bromo-5-formyl-4-((2-methoxyethoxy)methoxy)phenyl)succinate；dimethyl 2-[3-bromo-5-formyl-4-(2-methoxyethoxymethoxy)phenyl]butanedioate
• CAS: 878673-54-2
• 化学式: C₁₇H₂₁BrO₈
• 分子量: 433.253
• InChiKey: JDWSPMMHRZPBEH-UHFFFAOYSA-N

物化性质

• 沸点：
  502.9±50.0 °C(Predicted)
• 密度：
  1.397±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  26
• 可旋转键数：
  13
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  97.4
• 氢给体数：
  0
• 氢受体数：
  8

安全信息

• 海关编码：
  2918990090

反应信息

• 作为反应物：
  描述：

  2-(3-溴-5-甲酰基-4-((2-甲氧基乙氧基)甲氧基)苯基)琥珀酸二甲酯 在 tris(triphenylphosphano)palladium 、 氢溴酸 、 对苯醌 作用下， 以 甲醇 、 乙二醇二甲醚 为溶剂， 生成 2-[5-(5-carbamimidoyl-1H-benzoimidazol-2-yl)-5'-fluoro-6,2'-dihydroxy-biphenyl-3-yl]-succinic acid
  参考文献：
  名称：

  Factor VIIa inhibitors: Improved pharmacokinetic parameters

  摘要：

  Efforts to improve the potency and pharmacokinetic properties of small molecule factor VIIa inhibitors are described. Small structural modifications to existing leads allow the modulation of half-life and clearance, potentially making these compounds suitable candidates for drug development. (C) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.01.037
• 作为产物：
  描述：

  2-(4'-羟基苯基)丁烷-1,4-二酸 在 N-溴代丁二酰亚胺(NBS) 、 氯化亚砜 、 TEA 、 N,N-二异丙基乙胺 、 magnesium chloride 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 、 乙腈 为溶剂， 生成 2-(3-溴-5-甲酰基-4-((2-甲氧基乙氧基)甲氧基)苯基)琥珀酸二甲酯
  参考文献：
  名称：

  Factor VIIa inhibitors: Chemical optimization, preclinical pharmacokinetics, pharmacodynamics, and efficacy in an arterial baboon thrombosis model

  摘要：

  Highly selective and potent factor VIIa-tissue factor (fVIIa.TF) complex inhibitors were generated through structure-based design. The pharmacokinetic properties of an optimized analog (9) were characterized in several preclinical species, demonstrating pharmacokinetic characteristics suitable for once-a-day dosing in humans. Analog 9 inhibited platelet and fibrin deposition in a dose-dependent manner after intravenous administration in a baboon thrombosis model, and a pharmacodynamic concentration-response model was developed to describe the platelet deposition data. Results for heparin and enoxaparin (Lovenox) in the baboon model are also presented.

  DOI：

  10.1016/j.bmcl.2005.12.059

文献信息

• Factor VIIa inhibitors: Gaining selectivity within the trypsin family
  作者：William D. Shrader、Aleksandr Kolesnikov、Jana Burgess-Henry、Roopa Rai、John Hendrix、Huiyong Hu、Steve Torkelson、Tony Ton、Wendy B. Young、Bradley A. Katz、Christine Yu、Jie Tang、Ronnel Cabuslay、Ellen Sanford、James W. Janc、Paul A. Sprengeler

  DOI：10.1016/j.bmcl.2005.12.040

  日期：2006.3

  Within the trypsin family of coagulation proteases, obtaining highly selective inhibitors of factor VIIa has been challenging. We report a series of factor Vila (fVIIa) inhibitors based on the 5-amidino-2-(2-hydroxy-biphenyl-3-yl)-benzimidazole (1) scaffold with potency for fVIIa and high selectivity against factors IIa, Xa, and trypsin. With this scaffold class, we propose that a unique hydrogen bond interaction between a hydroxyl on the distal ring of the biaryl system and the backbone carbonyl of fVIIa lysine-192 provides a basis for enhanced selectivity and potency for fVIIa. (C) 2005 Elsevier Ltd. All rights reserved.